David-Alexandre C. Gros - Jan 10, 2025 Form 4 Insider Report for Eledon Pharmaceuticals, Inc. (ELDN)

Role
Chief Executive Officer, Director
Signature
/s/ Paul Little, as attorney-in-fact for David Alexandre C. Gros, M.D.
Stock symbol
ELDN
Transactions as of
Jan 10, 2025
Transactions value $
$0
Form type
4
Date filed
1/13/2025, 05:30 PM
Previous filing
Nov 22, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELDN Stock Option (right to buy) Award $0 +600K $0.00 600K Jan 10, 2025 Common Stock 600K $4.04 Direct F1
transaction ELDN Restricted Stock Units Award $0 +66.5K $0.00 66.5K Jan 10, 2025 Common Stock 66.5K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase up to 600,000 shares of common stock, which option vests with respect to 150,000 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
F2 Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration.
F3 Represents shares issuable on settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.